HOOKIPA Pharma Inc. HOOK
Jul 17, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- +28.78%
- 1 year
- -19.01%
- Market cap
- 24.47M
- Revenue (ttm)
- 52.16M
- Profit margin
- -93.16%
- Shares out
- 9.66M
- Forward P/E
- -0.37
- YTD return
- +28.78%
- 1-year return
- -19.01%
- Open
- 1.15
- Previous close
- 1.15
- Day's range
- 1.15 – 1.15
- Beta
- 0.83
- Analysts
- Buy
- Price target
- 23.50 (+1943.5%)
2Y -5.34 (-82.28%)
Key statistics
- Enterprise value
- -36.09M
- PEG ratio
- 0.00
- Price / sales
- 0.47
- Price / book
- 0.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -51.80%
- Free cash flow
- -46.05M
- Total cash
- 77.15M
- Total debt
- 4.90M
- Return on equity
- -48.99%
- Short % of float
- 0.47%
- 50-day average
- 3.09
- 200-day average
- 5.66
Analyst view
Consensus: buy
- Target (low)
- 7.00
- Target (mean)
- 23.50
- Target (high)
- 40.00
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.97.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.10 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -1.44 | -1.52 | -0.08 | -5.56% |
| May 9, 2024 | Mar 1, 2024 | -1.20 | 1.20 | +2.40 | +200.00% |
| Mar 22, 2024 | Dec 1, 2023 | -2.00 | -1.10 | +0.90 | +45.00% |
| Nov 9, 2023 | Sep 1, 2023 | -2.30 | -1.70 | +0.60 | +26.09% |
| Aug 10, 2023 | Jun 1, 2023 | -2.10 | -2.20 | -0.10 | -4.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Nov 21, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Nov 15, 2024 | RBC Capital | main | Outperform | Outperform |
| Aug 9, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jul 26, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jun 5, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hookipapharma.com
News
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics 
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead 
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock 
12 Health Care Stocks Moving In Thursday's Pre-Market Session - 12 Health Care Stocks Moving In Thursday's Intraday Session
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) 
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) 
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA 
HOOKIPA Pharma Inc - FORM 8 (OPD) 
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
Your note
Sign in to keep a note on HOOK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDAG JORN | Chief Executive Officer | Purchase | Jul 10, 2023 | 71,952 |
| COELHO MARY THERESA | Chief Financial Officer | Stock Award(Grant) | Jul 21, 2024 | 69,875 |
| KANDERA REINHARD | Chief Financial Officer | Purchase | Aug 20, 2023 | 43,092 |
| PETERS MALTE | Chief Executive Officer | Stock Award(Grant) | Jul 21, 2024 | 108,695 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 8.42% | 812,814 | 1.65M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 5.92% | 571,727 | 1.16M | Sep 29, 2024 |
| Siren, L.L.C. | 5.87% | 566,640 | 1.15M | Sep 29, 2024 |
| Knoll Capital Management, LLC | 5.71% | 551,738 | 1.12M | Sep 29, 2024 |
| FMR, LLC | 3.54% | 341,476 | 693.20K | Sep 29, 2024 |
| Vanguard Group Inc | 2.21% | 213,222 | 432.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.46% | 140,788 | 285.80K | Sep 29, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 1.05% | 101,448 | 205.94K | Oct 30, 2024 |
| Fidelity Capital Appreciation Fund | 0.95% | 91,620 | 185.99K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 69,843 | 141.78K | Sep 29, 2024 |
| Fidelity Advisor Equity Growth Fund | 0.69% | 66,861 | 135.73K | Oct 30, 2024 |
| Fidelity Growth Discovery Fund | 0.47% | 45,078 | 91.51K | Oct 30, 2024 |